Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(consultant)
56,922 results
  • [Early clinical drug development]. [Journal Article]
    Rev Prat 2019; 69(6):607-611Funck-Brentano C
  • The first administrations of a molecule to humans, so-called phase I studies of drug development, follow experimental animal studies which allow to have a first assessment of the pharmacological effects and toxicity of the molecule under development. Typically, these studies are performed in "healthy" subjects or in relapsing patients with cancer. Participants' safety is a priority. Trained profe…
  • Current and Future Pharmacological Therapies for the Management of Dry Eye. [Journal Article]
    Eye Contact Lens 2019Gupta PK, Asbell P, Sheppard J
  • Dry eye disease (DED) is among the most common reasons for visiting eye care practitioners and represents a substantial health and cost burden. Disease prevalence ranges from 5% to 33% and is increasing in the younger population. The core mechanism of DED involves a vicious cycle where hyperosmolarity leads to an inflammatory cascade resulting in ocular surface damage. No cure is available for DE…
  • Biosimilars for the treatment of psoriatic arthritis. [Journal Article]
    Expert Rev Clin Immunol 2019Cantini F, Benucci M, … Niccoli L
  • Introduction: In recent years, biosimilars of reference adalimumab (re-ADA), etanercept (re-ETN) and infliximab (re-IFX) have been licensed. In absence of specific controlled studies, by the extrapolation principle, biosimilars have been approved for the treatment of psoriatic arthritis (PsA). Areas covered: To assess the efficacy and safety of biosimilars in PsA, the literature, present until Ju…
New Search Next